Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
schizophrenia, Bristol Myers Squibb
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock rose after the pharma company won approval for its new schizophrenia drug late Thursday. “This drug takes the first new approach to schizophrenia treatment in decades,” the Food and Drug Administration said.
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
FDA approves schizophrenia drug that could alter how disorder is treated
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of a brain chemical called acetylcholine.
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
2d
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
health.wusf.usf.edu
1d
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
2d
on MSN
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More
Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Helene death toll rises
Actor John Ashton dies
'Days of Our Lives' star dies
NC dam failure ‘imminent’
Vance’s Pennsylvania rally
Hospitalized for burns
Rescue mission launched
Ga. chemical plant fire
Trump to visit Fayetteville
'SNL' launches 50th season
‘Wild Robot' tops box office
Condemns Israeli strikes
Malibu coast earthquake
Chief adviser subpoenaed
Haney sues Garcia
Temporary outage fixed
Szarewicz case update
ISR strikes Lebanon again
Faces fine to end Brazil ban
Congestion fee bid denied
Earth's orbit new asteroid
Ukrainian drones shot down
Steward CEO to step down
On Hezbollah leader's killing
Dow closes at record high
Van Gogh paintings attacked
121st loss of the season
Houthis attack US warships
Congressional Gold Medal
AL sued over purging voters
UNC digital IDs blocked
Human rabies death in MN
Feedback